ABSTRACT
PREDICT is a tool designed to estimate the benefits of adjuvant therapy and the overall survival of women with early breast cancer. The model uses clinical, histological, and immunohistochemical variables. This study aimed to evaluate the model's performance in a Brazilian population. We assessed the discrimination and calibration of the PREDICT model to estimate overall survival (OS) in five and ten years of follow-up in a cohort of 873 women with early breast cancer diagnosed from January 2001 to December 2016. A total of 743 patients had estrogen receptor (ER)-positive and 130 had ER-negative tumors. The area under the receiver operating characteristic (ROC) curve (AUC) for discrimination was 0.72 (95%CI: 0.66-0.78) at five years and 0.67 (95%CI: 0.61-0.72) at ten years for women with ER-positive tumors. The AUC was 0.72 (95%CI: 0.62-0.81) at five years and 0.67 (95%CI: 0.54-0.77) at ten years for women with ER-negative tumors. The predicted survival in ER-positive tumors was 91.0% (95%CI: 90.2-91.6%) at five years and 79.3% (95%CI: 77.7-81.0%) at ten years, and the observed survival 90.7% (95%CI: 88.6-92.9%) and 77.2% (95%CI: 73.4-81.4%), respectively. The predicted survival in ER-negative tumors was 84.5% (95%CI: 82.5-86.6%) at five years and 75.0% (95%CI: 71.6-78.5%) at ten years, and the observed survival 76.3% (95%CI: 69.1-84.3%) and 67.9% (95%CI: 58.6-78.6%), respectively. In conclusion, PREDICT was accurate to estimate OS in women with ER-positive tumors and overestimated the OS in women with ER-negative tumors.
Subject(s)
Breast Neoplasms , Humans , Female , Breast Neoplasms/drug therapy , Brazil/epidemiology , Cohort Studies , ROC CurveABSTRACT
PREDICT is a tool designed to estimate the benefits of adjuvant therapy and the overall survival of women with early breast cancer. The model uses clinical, histological, and immunohistochemical variables. This study aimed to evaluate the model's performance in a Brazilian population. We assessed the discrimination and calibration of the PREDICT model to estimate overall survival (OS) in five and ten years of follow-up in a cohort of 873 women with early breast cancer diagnosed from January 2001 to December 2016. A total of 743 patients had estrogen receptor (ER)-positive and 130 had ER-negative tumors. The area under the receiver operating characteristic (ROC) curve (AUC) for discrimination was 0.72 (95%CI: 0.66-0.78) at five years and 0.67 (95%CI: 0.61-0.72) at ten years for women with ER-positive tumors. The AUC was 0.72 (95%CI: 0.62-0.81) at five years and 0.67 (95%CI: 0.54-0.77) at ten years for women with ER-negative tumors. The predicted survival in ER-positive tumors was 91.0% (95%CI: 90.2-91.6%) at five years and 79.3% (95%CI: 77.7-81.0%) at ten years, and the observed survival 90.7% (95%CI: 88.6-92.9%) and 77.2% (95%CI: 73.4-81.4%), respectively. The predicted survival in ER-negative tumors was 84.5% (95%CI: 82.5-86.6%) at five years and 75.0% (95%CI: 71.6-78.5%) at ten years, and the observed survival 76.3% (95%CI: 69.1-84.3%) and 67.9% (95%CI: 58.6-78.6%), respectively. In conclusion, PREDICT was accurate to estimate OS in women with ER-positive tumors and overestimated the OS in women with ER-negative tumors.
ABSTRACT
A Pseudomonas aeruginosa é agente etiológico de infecções oportunistas, principalmente em pacientes imunocomprometidos. Suas características inerentes em desenvolver resistência aos mais variados tipos de antibacterianos a torna um ponto crítico no controle de infecções. Em animais, os problemas com multirresistência ocorrem principalmente em casos de otite, cistite, úveo-conjuntivite, endometrite e mastite, não havendo vacina comercialmente disponível. No intuito de melhorar a imunogenicidade desse antígeno, foi testada a técnica de conjugação do lipopolissacarídeo (LPS) de P. aeruginosa à albumina bovina (BSA) por aminação redutiva direta utilizando .-periodato de sódio. A conjugação foi avaliada por cromatografia de gel-permeação, dosando-se açúcar e proteína totais, e tanto o LPS quanto a BSA foram identificados em proporções semelhantes. A imunização de camundongos com a vacina conjugada LPS-BSA conferiu títulos de anticorpos aglutinantes contra P. aeruginosa inferiores aos obtidos com a mistura de LPS e BSA livres. Foram 65% e 86% menores na 6ª e na 10ª semanas após o procedimento de hiperimunização, respectivamente. Isto indica que a reação de conjugação resultou em um produto imunogênico, porém, sua qualidade precisará ser melhorada.
Pseudomonas aeruginosa is an etiologic agent of opportunistic infections mainly in immunocompromised patients. Its inherent feature of developing resistance to a wide range of antibacterial agents make it a critical point in infection control. In animals, problems with multidrug resistance occur in otitis, cystitis, uveo-conjunctivitis, endometritis and mastitis, and there is no commercially available vaccine. With the aim of improving its immunogenicity, the lipopolysaccharide (LPS) antigen was coupled to bovine serum albumin (BSA) with .-periodate as the reductive agent. The conjugation was evaluated by gel-permeation chromatography, by quantitating total sugar and protein, and both LPS and BSA were detected in similar proportions. The immunization of mice with LPS-BSA conjugate vaccine resulted in an agglutinating antibody response against P. aeruginosa lower than that obtained for a mixture of free LPS and BSA. They were 65% and 86% lower in the 6th and 10th weeks after the hyperimmunization procedure, respectively. This indicates that the conjugation reaction resulted in an immunogenic product, however its quality should be improved.
Subject(s)
Animals , Cattle , Pseudomonas aeruginosa , Serum Albumin, Bovine , Cattle Diseases , LipopolysaccharidesABSTRACT
ABSTRACT Pseudomonas aeruginosa is an etiologic agent of opportunistic infections mainly in immunocompromised patients. Its inherent feature of developing resistance to a wide range of antibacterial agents make it a critical point in infection control. In animals, problems with multidrug resistance occur in otitis, cystitis, uveo-conjunctivitis, endometritis and mastitis, and there is no commercially available vaccine. With the aim of improving its immunogenicity, the lipopolysaccharide (LPS) antigen was coupled to bovine serum albumin (BSA) with .-periodate as the reductive agent. The conjugation was evaluated by gel-permeation chromatography, by quantitating total sugar and protein, and both LPS and BSA were detected in similar proportions. The immunization of mice with LPS-BSA conjugate vaccine resulted in an agglutinating antibody response against P. aeruginosa lower than that obtained for a mixture of free LPS and BSA. They were 65% and 86% lower in the 6th and 10th weeks after the hyperimmunization procedure, respectively. This indicates that the conjugation reaction resulted in an immunogenic product, however its quality should be improved.
RESUMO A Pseudomonas aeruginosa é agente etiológico de infecções oportunistas, principalmente em pacientes imunocomprometidos. Suas características inerentes em desenvolver resistência aos mais variados tipos de antibacterianos a torna um ponto crítico no controle de infecções. Em animais, os problemas com multirresistência ocorrem principalmente em casos de otite, cistite, úveo-conjuntivite, endometrite e mastite, não havendo vacina comercialmente disponível. No intuito de melhorar a imunogenicidade desse antígeno, foi testada a técnica de conjugação do lipopolissacarídeo (LPS) de P. aeruginosa à albumina bovina (BSA) por aminação redutiva direta utilizando .-periodato de sódio. A conjugação foi avaliada por cromatografia de gel-permeação, dosando-se açúcar e proteína totais, e tanto o LPS quanto a BSA foram identificados em proporções semelhantes. A imunização de camundongos com a vacina conjugada LPS-BSA conferiu títulos de anticorpos aglutinantes contra P. aeruginosa inferiores aos obtidos com a mistura de LPS e BSA livres. Foram 65% e 86% menores na 6ª e na 10ª semanas após o procedimento de hiperimunização, respectivamente. Isto indica que a reação de conjugação resultou em um produto imunogênico, porém, sua qualidade precisará ser melhorada.
ABSTRACT
CBA/J mice are resistant to Leishmania major infection but are permissive to L. amazonensis infection. In addition, CBA/J macrophages control L. major but not L. amazonensis infection in vitro. Phagocytosis by macrophages is known to determine the outcome of Leishmania infection. Pattern recognition receptors (PRR) adorning antigen presenting cell surfaces are known to coordinate the link between innate and adaptive immunity. The macrophage receptor with collagenous structure (MARCO) is a PRR that is preferably expressed by macrophages and is capable of binding Gram-positive and Gram-negative bacteria. No research on the role of MARCO in Leishmania-macrophage interactions has been reported. Here, we demonstrate, for the first time, that MARCO expression by CBA/J macrophages is increased in response to both in vitro and in vivo L. major infections, but not to L. amazonensis infection. In addition, a specific anti-MARCO monoclonal antibody reduced L. major infection of macrophages by 30%-40% in vitro. The draining lymph nodes of anti-MARCO-treated mice displayed a reduced presence of immunolabelled parasite and parasite antigens, as well as a reduced inflammatory response. These results support the hypothesis that MARCO has a role in macrophage infection by L. major in vitro as well as in vivo.